Company Info
Phone(352) 448-7797
Year Established
1966
Ticker
AIM
Exchange
NYSE
Contacts
Thomas K. Equels, M.S. J.DCEO, President & Executive Chair
Peter W. Rodino III, J.D.
COO & General Counsel
Robert Dickey, IV
CFO
David Strayer, MD.
CMO
Christopher McAleer, Ph.D.
CSO
Company Description
AIM ImmunoTech is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders.